Battegay 1985.

Methods	Seven‐week, double‐blind, randomised study.
Participants	Outpatients meeting DSM III endogenous and reactive depression, with a minimum score of 20 on the Hamilton rating scale for depression (HDRS‐17). Age range: 18‐60 years.
Interventions	Paroxetine: 11 participants. Amitriptyline: 10 participants. Paroxetine dose range: 10‐30 mg/day. Amitriptyline dose range: 50‐100 mg/day. In case of severe insomnia tranquillisers with a short half life were permitted.
Outcomes	HDRS‐17, Montgomery and Asberg Depression Rating Scale (MADRS), Clinical Global Impression (CGI). Dropout, number of patients experiencing at least one side effect, side‐effect profile.
Notes	Small sample; more than 50% of patients did not complete the trial.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "the patients received (...) in a randomized procedure (...)". No further details.
Allocation concealment (selection bias)	Unclear risk	No informations provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "the patients received in a double blind procedure identically looking white tablets containing either 10 mg paroxetine ore 50 mg amitriptyline".
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind".
Incomplete outcome data (attrition bias) All outcomes	High risk	Study endpoint: 3/11 missing from paroxetine group; 8/10 missing from control group.
Selective reporting (reporting bias)	High risk	Standard deviations of change scores for depression were not reported.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.